Personalizing Therapy in Advanced Non–Small Cell Lung Cancer
Explore this paper's citation graph
Summary
The state of personalized lung cancer therapy as it pertains to individual NSCLC genotypes is outlined, with a focus on oncogenic drivers in 62% lung adenocarcinomas and an increasing proportion of squamous cell carcinomas of the lung.
- Type
- article
- Published
- 2013-11-20
- Cited by
- 18
- References
- 163
- Access
- Open access
- OpenAlex
- https://openalex.org/W24258572
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5141141
Keywords
Computer science
References
- Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
- 31.縦隔型Small Cell Lung Cancerの一症例(第28回日本肺癌学会中国・四国支部会)
- A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
- EGFR mutant lung cancer.
- Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.
- Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party.
- Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors.
- Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?
- Chemotherapy in Non-Small Cell Lung Cancer
- PIK3CA is implicated as an oncogene in ovarian cancer
- Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
- The Prognostic and Predictive Value of KRAS Oncogene Substitutions in Lung Adenocarcinoma
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
- Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
- KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre
- Epidermal growth factor receptor mutations in lung cancer
- Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
- Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
- MET: a promising anticancer therapeutic target
Cited by
- Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.
- Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?
- Immunotherapy in lung cancer.
- Clinicopathologic Features of Advanced Squamous NSCLC.
- Molecular gene signature and prognosis of non-small cell lung cancer
- Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation
- Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing
- Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer
- LINC00852 is associated with poor prognosis in non‐small cell lung cancer patients and its inhibition suppresses cancer cell proliferation and chemoresistance via the hsa‐miR‐145‐5p/KLF4 axis
- Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.
- Observation on the Effect of High-Quality Nursing Intervention plus Health Education in Chemotherapy for Non-Small Cell Lung Cancer and Its Influence on the Physical and Mental Health of Patients
- Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine
- Integrated multi-omics data reveals the molecular subtypes and the contruction of novel signature to aid Immunotherapy
- LINC00852 participates in the phycocyanin-mediated restrained vitality of non-small cell lung cancer cells via miR-29a-3p/LAMTOR1 axis
- Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug
- Nanoformulations: Reforming treatment for non-small cell lung cancer metastasis.
- Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available to the Pulmonologist
- Cancers of the Respiratory System
Related papers
No related papers recorded.